Lantern Pharma reports Q4 2024 net loss $5.9M ($0.54/share); cash $24M as pipeline advances

Lantern Pharma Inc.

Net loss for Q4 2024 was $5.9M ($0.54 per share) vs $4.2M ($0.39) in Q4 2023; full year net loss $1.93/share vs $1.47.
Cash, cash equivalents and marketable securities $24.0M as of Dec 31, 2024, down from $41.3M at Dec 31, 2023.
HARMONIC trial lead-in cohort (LP-300) showed 86% clinical benefit rate and 43% ORR in never-smoker NSCLC; expansion cohort reinforcing trends.
LP-184 received two FDA Fast Track Designations (GBM, TNBC) and three Rare Pediatric Disease Designations; Phase 1a on cohort 11.
RADR platform surpassed 100B oncology data points; MD Anderson collaboration shows LP-184 synergy with anti-PD1 in TNBC preclinical models.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.